NCT04006080View on ClinicalTrials.gov

Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

Vedolizumab

Intravenously administered selective leukocyte adhesion molecule inhibitor

Trial Locations (1)

Unknown

RECRUITING

Guy's and St Thomas' NHS Foundation Trust, London

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Guy's and St Thomas' NHS Foundation Trust

OTHER